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Abstract
Background: Solid-pseudopapillary neoplasms (SPNs) of the pancreas are increasingly diag-
nosed, but the exact surgical management in terms of extent of the resection is not well deﬁned.
Materials and Methods: Patients operated on in our hospital between January 1993 and March
2005 formed the study groups.
Results: From 659 consecutive resections for pancreatic neoplasms, 12 female patients (1.8%)
with a median age of 21 years who underwent resection for (SPN) are compared with the
remaining 647 pancreatic resection patients. Jaundice (SPN 0 versus PR 73%, p < 0.001) and
weight loss (SPN 0 versus PR 49%, p = 0.001) occurred signiﬁcantly less often. Neoplasms were
distributed equally among the pancreatic head (SPN 5 out of 12 patients versus PR 88%,
p < 0.001) and corpus/tail (SPN 6 out of 12 patients versus PR 8%, p < 0.001). The operative time
was signiﬁcantly shorter (SPN 233 min versus PR 280 min, p = 0.012), and there were signiﬁ-
cantly fewer complications (SPN 1 of 12 patients versus PR 48%, p = 0.007). The mortality was
not different (SPN 0 versus PR 1.6%, p = 1.000), and the hospital stay was signiﬁcantly shorter
(SPN 9 days versus PR 15 days, p = 0.012). The median size of the neoplasms was signiﬁcantly
larger (SPN 6.9 cm versus PR 2.5 cm). The median number of lymph nodes harvested was
signiﬁcantly fewer (SPN 1 versus PR 6, p = 0.001), and lymph node metastases occurred
signiﬁcantly less often (SPN 0 versus PR 64%, p < 0.001). The 5-year survival of SPN patients
was 100% and is signiﬁcantly better compared with survival of patients with pancreatic adeno-
carcinoma (12%, p < 0.001) and ampulla of Vater adenocarcinoma (22%, p = 0.005).
Conclusions: Patients with solid-pseudopapillary neoplasms of the pancreas present differently
and the course of the disease is more benign. These patients can be adequately managed by
pylorus-preserving pancreatoduodenectomy or spleen-preserving distal pancreatectomy with
excellent early and long-term results.
S
olid-pseudopapillary neoplasm (SPN) of the pan-
creas was ﬁrst reported by Frantz in 1959.
1 Further
speciﬁcation by Hamoudi led to its acceptance as a
separate clinicopathological entity.
2 There have been
controversies regarding the terminology, and it has been
concluded that the semantically correct description is
solid-pseudopapillary neoplasm.
3 The neoplasm re-
mained essentially unrecognized up to the early 1990s,
and fewer than 300 cases were reported up until 1995.
4
However, with increased awareness among surgeons,
radiologists, and pathologists and the widespread avail-
ability of new high-quality imaging systems, the number
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approximately 600 annually.
5 Solid-pseudopapillary neo-
plasms make-up approximately 1%–2% of all pancreatic
neoplasms.
6,7
The cumulative experience to date has provided inter-
esting insights into this disease. Most patients (up to
90%) are female and usually in the second or third dec-
ade of life.
4,8–11 The neoplasms have a low malignant
potential, with a reported incidence of malignant trans-
formation of around 15%.
11 The biological behavior in
terms of metastasis or local invasion is the most accepted
criterion for malignant transformation.
4,9 This low level of
aggressiveness corresponds to the high cure rate.
11
Malignant SPN is still compatible with long-term survival
in patients undergoing radical resection of the neoplasm.
6
The surgical management of these neoplasms is still
not well deﬁned.
4,6,8 There are no deﬁnite recommenda-
tions in the literature regarding to the extent of resection
of the primary neoplasm and management of metastasis.
These features of the disease assume increased impor-
tance because more patients with these neoplasms are
being diagnosed preoperatively and are advised to un-
dergo pancreatic resection.
The aim of the present study was therefore to ana-
lyze the clinical presentation, diagnostic work-up, man-
agement, and outcome of patients with SPNs of the
pancreas, and to compare the results with patients who
undergo resection for all other pancreatic neoplasms.
PATIENTS AND METHODS
The prospective pancreatic database (January 1993–
March 2005) of the department of Surgery and Pediatric
SurgeryoftheAcademicMedicalCenter,Amsterdam,was
used to identify patients with SPNs of the pancreas man-
agedinthisperiod.Thepatientswithpathologicallyproven
SPN formed the study group and were compared to a
pancreatic resection group (PR) consisting of all other
patients who underwent resection for pancreatic neo-
plasms. Procedures included pancreatoduodenectomy,
central pancreatectomy, and distal pancreatectomy. Enu-
cleations for neuroendocrine neoplasms were excluded.
The patient records were used to collect demographic,
clinical, operative, and pathologic data. The preoperative
data included age at presentation, sex, symptoms,
imaging studies, and clinical diagnosis. Weight loss was
deﬁned as a loss of 10% of body weight during the pre-
vious year. The patients in whom a preoperative diag-
nosis of SPN of the pancreas was made were studied
separately to identify the clinical and imaging character-
istics that led to the diagnosis. The surgical parameters
analyzed included the location of the neoplasm, evidence
of malignancy (metastasis or local invasion), and the type
of procedure performed.
Postoperative complications and length of hospital stay
were recorded. The deﬁnitions of complications used for
the present study have been reported previously.
12,13 In
short, pancreatic ﬁstula was deﬁned as abdominal drain
ﬂuid with amylase levels three times the normal serum
levels. Delayed gastric emptying after PPPD was deﬁned
as either the need for nasogastric intubation for 10 days
or more or the inability to tolerate regular food before or
on postoperative day (POD) 14. In-hospital mortality was
deﬁned as death hospitalization stay or during readmis-
sion within 30 days.
The histopathological data analyzed comprised the size
of the neoplasm; radicality of resection; involvement of
lymph nodes and histological features suggestive of
malignancy, perineural or angioinvasion, or invasion into
the surrounding tissue; and immunohistochemical stain-
ing. A curative resection (R0) was characterized by a
specimen with no gross tumor mass remaining at the
operation site or in other organs and microscopic clear
resection margins. An R1 resection was deﬁned as
microscopic involvement of the resection margin, and R2
was deﬁned by microscopically conﬁrmed macroscopic
tumor remaining at the operation site. Only lymph nodes
surrounding the pancreas anteriorly and posteriorly, in the
hepatoduodenal ligament, and right of the common he-
patic artery and superior mesenteric vein were removed.
The follow-up data was recorded through review of the
hospital records, the outpatient visits, and telephonic
interview.
Data analyses were performed using SPSS
  software
(SPSS, Chicago, Illinois, USA). A value of p < 0.05 was
considered statistically signiﬁcant. Univariate analysis
was carried out with Pearson’s v
2 test to determine which
variables were statistically signiﬁcant. Fisher’s exact test
was used when a table had a cell with an expected fre-
quency of less than 5.
RESULTS
Histopathological features that conﬁrmed the diagnosis
of SPN of the pancreas were found in 12 of the 659 con-
secutive patients (1.8%) who underwent pancreatic
resection during the study period. All 12 patients were
female with a median age of 21 (range: 13–55) years
(Table 1). Abdominal pain was the most common pre-
senting symptom, and it occurred in 8 patients (67%).
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versus PR 73%, p < 0.001), and weight loss (SPN 0 ver-
sus PR 49%, p = 0.001) occurred signiﬁcantly less often.
Contrast-enhanced computed tomography (CT) scan of
the abdomen was performed in all patients. The CT scan
ﬁndings suggestive of the diagnosis of SPN were a large
heterogeneous mass with solid and cystic components,
as well as areas of hyperattenuation representing intra-
mural hemorrhage.
Three patients underwent preoperative ﬁne-needle
aspiration cytology (FNAC). The FNAC was inconclusive
in the one patient and conﬁrmed SPN in two. The pre-
operative diagnosis in the ﬁrst four consecutive patients
was serous cystic neoplasm after CT scan, all diagnosed
before 2000. After 2000, 6 patients were preoperatively
diagnosed as having a SPN, and one 54-year-old patient
was thought to have a serous cystic neoplasm. The lesion
was located in the head of the pancreas in ﬁve patients.
All of these patients underwent a pylorus preserving
pancreatoduodenectomy. The remainder of the patients
had a distal neoplasm (corpus or tail).
Distal pancreatectomy was performed in six patients.
The spleen was preserved in two out of six patients who
underwent distal pancreatectomy. Spleen preservation
was not possible in one patient because of vascular
involvement (splenic artery and vein), one had hilar
involvement, one had splenomegaly, and one was man-
aged in the early years of the series. Liver metastases in
the right liver lobe were detected in one patient and a right
hemihepatectomy was performed 5 months later. A
central pancreatectomy was performed in one patient.
Neoplasms occurred less often in the pancreatic head
(SPN in 5 of 12 patients versus PR 88%, p < 0.001) and
more often in the corpus/tail (SPN 6 of 12 patients versus
PR 8%, p < 0.001). Central neoplasms suitable for central
pancreatectomy (SPN 1 of 12 patients versus PR 3%,
p = 0.311) did not differ between groups. The operative
time was signiﬁcantly shorter (SPN 233 min versus PR
280 min, p = 0.012).
One patient developed a postoperative complication
and no in-hospital mortality occurred. One patient devel-
oped cholangitis postoperatively which was successfully
managed (conservatively) with antibiotics. There were
signiﬁcantly less postoperative complications (SPN 1 pa-
tient of 12 versus PR 48%, p = 0.007) and the postoper-
ative hospital stay was signiﬁcantly shorter (SPN 9 days
versus PR 15 days, p = 0.012). The in-hospital mortality
was comparable (SPN 0 versus PR 1.6%, p = 1.000).
Atpathology(Table 2),themediansizeoftheneoplasms
was 6.9 (range: 3–16) cm and all neoplasms were well
circumscribed with no local inﬁltration on gross examina-
tion. At histopathologic examination, all resections were
radical (R0). No differences could be recognized in the
microscopic picture between 11 patients with benign SPN
and the one with metastatic SPN. Lymph node metastasis
was not found in any of the patients (including the meta-
static SPN). The median neoplasm size was signiﬁcantly
larger (SPN 6.9 cm versus PR 2.5 cm, p < 0.001) and
positive lymph nodes (SPN 0 versus PR 64%, p < 0.001)
occurred signiﬁcantly less often. Immunohistochemical
Table 1.
Characteristics of patients who underwent pancreatic resection
1
Pancreatic resection for neoplasms SPN p Value
(n = 647) (n = 12)
Age (median, range) 63 (28–88) 21 (13–55) < 0.001
4
Gender (male:female) 350 : 297 0:12 0.002
2
Symptoms
Jaundice (%) 474 (73) 0 <0.001
3
Weight loss (%) 317 (49) 0 0.001
2
Pain (%) 266 (41) 8 0.084
3
Surgery
PD or PPPD (%) 570 (88) 5 < 0.001
3
Tail resection (%) 50 (8) 6 < 0.001
3
Corpus resection (%) 19 (3) 1 0.311
3
Complications (%) 310 (48) 1 0.007
Operative time (median, range) 280 (40–685) 223 (120–390) 0.012
4
Mortality (%) 10 (1.6) 0 1.000
3
Postoperative hospital stay in days (median, range) 15 (6–222) 9 (6–18) < 0.001
4
PD: pancreatoduodenectomy; PPPD: pylorus preserving pancreatoduodenectomy; SPN: solid-pseudopapillary neoplasm.
1Numbers in parentheses are percentages.
2v
2 test.
3Fisher’s exact test.
4Mann-Whitney U-test.
De Castro et al.: Pancreatic Solid-pseudopapillary Neoplasms 1131staining (Table 3) was performed on 11 specimens and
positive for CD56, vimentin and b-catenin in all patients,
further conﬁrming the diagnosis of SPN.
At a median follow-up of 3.8 years (range: 2–12.6
years) all SPN patients are alive and well. The survival is
signiﬁcantly better compared to pancreatic adenocarci-
noma and ampulla of Vater adenocarcinoma, the two
most common neoplasms in the pancreatic resection
group (Fig. 1). In the present study the number of cases
was equal to the number of signiﬁcant variable found in
univariate analysis, and therefore a multivariate analysis
was not performed.
DISCUSSION
The present study reports the results of the surgical
management of SPNs of the pancreas and found that
patients generally present with abdominal pain. These
patients have large neoplasms, which are equally dis-
tributed among proximal and distal pancreas. Pylorus-
preserving pancreatectomy and distal pancreatectomy
resulted in a microscopic R0 in all patients, with virtually
no postoperative complications and no in-hospital mor-
tality.
Contrast-enhanced CT scan of the abdomen with thin
slices was the imaging modality used for the diagnosis of
these neoplasms. An appropriate clinical setting (i.e., a
young and female patient) together with the appearance
of a heterogeneously enhancing solid-cystic neoplasm
resulted in the preoperative diagnosis. There are studies
that report that magnetic resonance imaging (MRI) scan
may be superior for the diagnosis of SPN because it
better depicts the neoplasm capsule and the intratumoral
hemorrhage that is frequently associated with SPN.
14,15
A CT scan or MRI scan should be conclusive so that
FNAC is not necessary before surgery is planned, and
furthermore resection is indicated in patients with a
resectable pancreatic mass.
The experience with ﬁne FNAC (percutaneous or EUS
guided) for the diagnosis of SPN is limited.
5,16 In the
present study, after percutaneous FNAC in three pa-
tients, a deﬁnitive diagnosis of SPN was reached in two.
A recent study reported a ‘‘preliminary’’ diagnosis of SPN
in only one of six patients, the other diagnoses being low-
grade neoplasm in two and endocrine neoplasm in three.
5
Fine-needle aspiration cytology therefore may be useful
in obtaining the diagnosis, but it usually is not necessary.
Surgery for SPN of the pancreas is increasingly being
performed because these neoplasms are now being
diagnosed more frequently.
5 This is reﬂected in the
present study, where seven patients with this rare neo-
plasm were managed in the last 2 years of the studied
period.
Preserving surgery for SPN of the pancreas is advo-
cated by one other study in the literature.
8 The role of
more limited surgery in the form of neoplasm enucleation
Table 3.
Immunohistochemical staining of solid-pseudopapillary
neoplasms of the pancreas (n = 11)
Stain Positive (%) Negative (%)
N-CAM/CD56 11 0
Chromogranin A 2 9
Synaptophysin 2 9
Vimentine 11 0
Cytokeratine 1 10
Neurospeciﬁc enulase 11 0
CD10 11 0
Alfa-1-antitrypsin 9 2
B-catenin 11 0
CAM 5.2 11 0
Table 2.
Pathology ﬁndings for patients undergoing pancreatic resection versus those undergoing solid-pseudopapillary neoplasm
1
Pancreatic resection for neoplasms SPN p Value
(n = 647) (n = 12)
Median neoplasm size in cm (range) 2.5 (0.3–11.0) 6.9 (3.0–16.0) <0.001
3
Malignancy 525 (81) 1
2 <0.001
4
R0 resection 395 (61) 12 0.005
4
Median no. of lymph nodes harvested (range) 6 (0–29)
5 1 (0–11) 0.001
6
Positive lymph nodes 336 (52) 0 <0.001
6
1Numbers in parentheses are percentages.
2One patent had metastatic lesions (0.5 cm and 1.5 cm), both in segment 8.
3Mann-Whitney U-test.
4Fisher’s exact test.
6Including the specimens of patients with benign neoplasms.
6v
2 test.
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agement of SPN by this approach.
9 Enucleation was not
preformed in the present study because of the high risk of
pancreatic ﬁstula.
17,18
Pylorus-preserving pancreatoduodenectomy and
spleen-preserving distal pancreatic resections are now
acceptable procedures. However, spleen preservation
was possible in only two of six distal pancreatectomies
performed in the present study. The spleen can be safely
preserved without preservation of the splenic artery and
vein.
19 Spleen preservation may also become difﬁcult
because of the relatively large size of the neoplasms. The
value of a central pancreatic resection is obviously that
more pancreatic tissue is spared in these young patients.
However, in view of the soft pancreas that is present in
these patients with consequent higher chances of pan-
creaticoenteric anastomotic leak, it remains controver-
sial.
18 It may be argued that this type of surgery should be
restricted to specialized centers with adequate experi-
ence.
The experience with the management of disseminated
disease is very limited in the literature. Liver metastases
are quite uncommon with SPN, and in many patients their
removal results in long-term survival.
6,7 Long-term sur-
vival has also been reported in patients whose liver
metastases were not resected.
20,22 In these reported
series, two patients with liver metastasis had signiﬁcant
overall survival, with one alive at 11 years and the other
alive with liver recurrence at 4 years.
There are no reports in the literature that describe the
sensitivity to radiotherapy or chemotherapy, and such
adjuvants probably have no effect on these neoplasms.
One of the questions pertaining to the surgical manage-
ment of SPN that remains unanswered is the extent of
resection for liver metastases. The only such patient in
the current series, managed by right hemihepatectomy
over a decade ago, is currently disease free. However,
keeping in mind the biological behavior of the neoplasm,
a metastectomy with a 1-cm margin would probably be
sufﬁcient. Similarly, peritoneal metastases are very rare,
and there are reports of long-term survival after debul-
king.
21 Ingrowth into adjacent organs like stomach or
spleen would necessitate the excision of part of the in-
volved organs. However, in patients where the involve-
ment is extensive enough to preclude resection, extended
survival is still possible.
20
The incidence of lymph node metastasis is extremely
rare.
6 A review of 292 SPNs reported 43 as malignant
(15%), and of these, lymph nodes were involved in only
ﬁve patients (2%).
4 Thus, a formal lymphadenectomy is
not indicated in patients with (malignant) SPN and was
not routinely performed in the present study.
In conclusion, patients with solid-pseudopapillary neo-
plasms of the pancreas present differently from patients
with other pancreatic neoplasms. The present study
suggests a standardized policy of resection for patients
with SPN in view of the relatively benign behaviour of
these neoplasms, the young age of these patients, and
the complete alleviation of all symptoms after resection
with no mortality. The patients with a lesion localized to
the head of the pancreas should undergo PPPD, and
lesions in the tail should be treated with a spleen-pre-
serving distal pancreatectomy. Selected neoplasms of
the body of the pancreas (small size) can be managed by
corpus resection if experience is at hand.
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